Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 4/20 | 0.55 |
| ▸ | CDK2 | P24941 | 4/20 | 0.55 |
| ▸ | CDK9 | P50750 | 4/20 | 0.55 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.55 |
| ▸ | BRD4 | O60885 | 6/20 | 0.54 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | CTSC | P53634 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 2/20 | 0.51 |
| ▸ | JAK1 | P23458 | 2/20 | 0.51 |
| ▸ | SYK | P43405 | 3/20 | 0.50 |
| ▸ | JAK3 | P52333 | 1/20 | 0.50 |
| ▸ | ITK | Q08881 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 2/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.49 |
| ▸ | CDK7 | P50613 | 2/20 | 0.49 |
| ▸ | CCNH | P51946 | 2/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.49 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2566155 | 0.87 | CCNT1 (0.54) | CCNT1CDK2CDK9CCNE1BRD4 | |
| Hydrochloric Acid SCHEMBL14482069 | 0.86 | CCNT1 (0.53) | CCNT1CDK2CDK9CCNE1BRD4 | |
| SCHEMBL12854308 | 0.85 | SYK (0.71) | CCNT1CDK2CDK9CCNE1BRD4 | |
| SCHEMBL12519555 | 0.82 | SYK (0.65) | EGFRSYKITK | |
| SCHEMBL13498447 | 0.80 | EGFR (0.56) | EGFRSYKITK | |
| SCHEMBL14551117 | 0.79 | PRKCQ (0.42) | CCNT1CDK2CDK9CCNE1BRD4 | |
| SCHEMBL14482337 | 0.79 | JAK2 (0.49) | CCNT1CDK2CDK9CCNE1BRD4 | |
| SCHEMBL2745650 | 0.78 | SYK (0.56) | EGFRSYKITK | |
| SCHEMBL2560511 | 0.78 | EGFR (0.55) | CDK2CDK9BRD4EGFRCTSC | |
| SCHEMBL12854318 | 0.78 | SYK (0.72) | CCNT1CDK2CDK9CCNE1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518937-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | claimed |
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | claimed |
| US-8278299-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | claimed |
| EP-2382210-A2 | PYRIMIDINEDIAMINE KINASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2011-11-02 | — | — | EP | claimed |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | claimed |
| WO-2010078369-A2 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | claimed |
| US-9040527-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040527-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040527-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20130309228-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130309228-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8518937-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518937-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8278299-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278299-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| EP-2382210-A2 | PYRIMIDINEDIAMINE KINASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| WO-2010078369-A2 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | CCNT1 474/4885CDK2 19/4885CDK9 21/4885 |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | CCNT1 361/4885CDK2 18/4885CDK9 25/4885 |
| US-20130309228-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | CCNT1 474/4885CDK2 19/4885CDK9 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.